Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.45 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | KCNJ1 | P48048 | 10/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15511318 | 1.00 | GPR119 (0.45) | GPR119ACACBKCNJ1PDE4DMGLL | |
| SCHEMBL15495838 | 1.00 | GPR119 (0.45) | GPR119ACACBKCNJ1PDE4DMGLL | |
| SCHEMBL15511796 | 0.87 | GPR119 (0.54) | GPR119PDE4D | |
| SCHEMBL15495656 | 0.87 | GPR119 (0.54) | GPR119PDE4D | |
| SCHEMBL15511518 | 0.85 | GPR119 (0.42) | GPR119ACACBKCNJ1PDE4DUSP2 | |
| SCHEMBL15511515 | 0.85 | GPR119 (0.42) | GPR119ACACBKCNJ1PDE4DUSP2 | |
| SCHEMBL15512171 | 0.81 | SLC6A9 (0.52) | GPR119 | |
| SCHEMBL13733375 | 0.81 | SLC6A9 (0.52) | GPR119 | |
| SCHEMBL15495701 | 0.81 | SLC6A9 (0.52) | GPR119 | |
| SCHEMBL15495657 | 0.81 | SLC6A9 (0.52) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140066369-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | claimed |
| US-20140066369-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066369-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | GPR119, GLP1R, SLC5A2 | GPR119 1/4885ACACB 2032/4885KCNJ1 828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.